EUVIMEDEUVIMED entdecken
Open Access

Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists

Ryan E Murphy iD, Pingyuan Wang iD, Saghir Ali, Hudson R Smith, Daniel E Felsing, Haiying Chen, Jia Zhou iD, John A Allen

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Ryan E Murphy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555…. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Benzamides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse, Pharmaceutical Research and Manufacturers of America Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orphan GPR52 is emerging as a promising neurotherapeutic target. Optimization of previously reported lead 4a employing an iterative drug design strategy led to the identification of a series of unique GPR52 agonists, such as 10a (PW0677), 15b (PW0729), and 24f (PW0866), with improved potency and efficacy. Intriguingly, compounds 10a and 24f showed greater bias for G protein/cAMP signaling and induced significantly less in vitro desensitization than parent compound 4a, indicating that reducing GPR52 β-arrestin activity with biased agonism results in sustained GPR52 activation. Further exploration of compounds 15b and 24f indicated improved potency and efficacy, and excellent target selectivity, but limited brain exposure warranting further optimization. These balanced and biased GPR52 agonists provide important pharmacological tools to study GPR52 activation, signaling bias, and therapeutic potential for neuropsychiatric and neurological diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledBenzamidesHumansAnimalsStructure-Activity RelationshipHEK293 CellsDrug DiscoveryMiceRatsSignal Transduction

Substanzen

Receptors, G-Protein-CoupledGPR52 protein, humanBenzamides

Autor:innen und Institutionen

  • Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.

ORCID-Profile: Ryan E Murphy, Pingyuan Wang, Jia Zhou

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse
  • Pharmaceutical Research and Manufacturers of America Foundation
  • University of Texas Medical Branch

Zitieren

APA

Murphy, R. E., Wang, P., Ali, S., Smith, H. R., Felsing, D. E., Chen, H., Zhou, J., & Allen, J. A. (2024). Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00856

Vancouver

Murphy RE, Wang P, Ali S, Smith HR, Felsing DE, Chen H, et al. Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00856

BibTeX
@article{Murphy2024,
  author = {Murphy, Ryan E and Wang, Pingyuan and Ali, Saghir and Smith, Hudson R and Felsing, Daniel E and Chen, Haiying and Zhou, Jia and Allen, John A},
  title = {Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00856}
}
Kostenlos starten →